The in vivo efficacy of Ctx-W52D was also maintained in the G465R-EGFR-COLO320DM xenograft model; however, there was no significant difference between the cetuximab group and PBS group in tumor growth suppression (Fig. 7q–s). Here, EGFR is linked to neoplasm.